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Abstract
Catabolic insufficiency in humans leads to the gradual accumulation of a number of pathogenic
compounds associated with age-related diseases, including atherosclerosis, Alzheimer's disease,
and macular degeneration. Removal of these compounds is a widely researched therapeutic option,
but the use of antibodies and endogenous human enzymes has failed to produce effective
treatments, and may pose risks to cellular homeostasis. Another alternative is "medical
bioremediation," the use of microbial enzymes to augment missing catabolic functions. The
microbial genetic diversity in most natural environments provides a resource that can be mined for
enzymes capable of degrading just about any energy-rich organic compound. This review discusses
targets for biodegradation, the identification of candidate microbial enzymes, and enzyme-delivery
methods.
Introduction
The continuous renewal of biological components is
essential for the proper functioning and survival of mam-
malian cells. While numerous innate means exist for the
elimination of damaged intra- and extra-cellular compo-
nents, inherent imperfections of these processes inevita-
bly lead to the gradual accumulation of certain
compounds. While less of a problem in short-lived or
dividing cells, deleterious accumulations may accelerate
with increasing age and contribute to the pathogenesis of
several major age-related diseases. In fact, it has been pro-
posed that this catabolic insufficiency is one of the princi-
ple causes of aging [1-3]. Accordingly, it has been
suggested that removal of specific pathogenic compounds
that accumulate intracellularly would ameliorate symp-
toms of certain diseases or aging in general [4,5]. One sug-
gested means of treatment, termed "medical bioreme-
diation," involves the targeted use of exogenous enzymes
(or the genes that encode them) to supply missing or
enhance insufficient catabolic functions [5]. Medical
bioremediation can be considered as an extension of envi-
ronmental bioremediation, which is "a managed or spon-
taneous process in which biological, especially
microbiological, catalysis acts on pollutant compounds,
thereby remedying or eliminating environmental contam-
ination present in water, wastewater, sludge, soil, aquifer
material, or gas streams" [6].
Normal turnover of biological structures occurs through
numerous pathways. Cytosolic proteins are typically
degraded either by the proteosome [7] or a group of cal-
cium-dependent proteases, calpains [8]. Mitochondria
utilize Lon matrix proteases [9] and membrane-embed-
ded AAA proteases [10]. Lysosomes, containing a reper-
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toire of hydrolytic enzymes, are capable of degrading a
wide variety of macromolecules. A common feature of
senescent cells is a reduction in the efficiency of these cat-
abolic pathways [9,11-13]. As a result, cytosolic accumu-
lation of abnormal proteins may occur [12]. The
modification of these proteins is thought to be mostly a
consequence of post-translational damage that takes place
through exposure to reactive oxygen species (ROS) or
excess glucose [14]. Another major component of aged
cells is lipofuscin, an intralysosomal polymeric material
of oxidized protein and lipid found to resist degradation
and exocytosis [15]. Oxysterols, generated through oxida-
tive processes within the lysosome [16], may also accumu-
late intracellularly. Though typically only present at
micromolar concentrations, these oxidized derivatives of
cholesterol have broad and potent biological activity
[17,18]. Extracellularly, amyloid deposits and advanced
glycation end-products (AGEs) predominate [19,20].
Although widely diverse in structure and function, each of
these compounds disrupts cellular and tissue homeosta-
sis, and accelerates or causes pathogenesis.
The feasibility of medical bioremediation is supported by
research showing that proliferating cells may escape accu-
mulation-related senescence through continual dilution,
while post-mitotic cells do not. It has also been shown
that inhibition of autophagic sequestration or degrada-
tion gradually decreased cell viability in confluent fibrob-
lasts, eventually resulting in apoptosis or necrosis [21].
Additional rationale for medical bioremediation comes
from the success of enzyme replacement therapy (ERT) in
treating lysosomal storage diseases (LSD), a group of
inherited disorders resulting from enzymatic deficiency
[22-24]. ERT utilizes intravenous injections of exogenous
enzyme to replace the non-functional or deficient endog-
enous enzyme. More recently, preservation of chaperone-
mediated autophagy (CMA), which declines with age
[25], was reported to restore function in aged mouse livers
[26]. This illustrates the possible therapeutic value of
removing harmful intracellular aggregates.
This article reviews several major age-related diseases and
discusses how they may benefit from medical bioremedi-
ation. In addition to detailing how biodegradation of par-
ticular aggregates may help prevent these diseases, we
provide examples of exogenous enzymes (and the genes
than encode them) that may be of therapeutic value.
Then, we discuss delivery methods, along with their mer-
its and limitations. Finally, we conclude with a perspec-
tive on research needs and potential institutional and
commercial barriers to overcome for broad implementa-
tion.
Atherosclerosis
Atherosclerosis is a progressive disease of the arterial
blood vessels and the principle contributor to the patho-
genesis of myocardial and cerebral infarction. As such, it
is the leading cause of all mortality in the United States,
Europe, and Japan [27]. Though the disease is highly
ubiquitous, it has an extremely complex etiology that hin-
ders the development of effective treatments. The earliest
symptoms are lesions known as "fatty streaks," an aggre-
gation of lipid-rich macrophages and T-lymphocytes
within the sub-endothelial matrix that may be a result of
arterial injury [28]. Remarkably, these early-stage lesions
were found to exist in half of autopsy samples from chil-
dren aged 10 to 14 [29]. Initiation and progression of
"fatty steaks" to fibrous plaques is an inflammatory proc-
ess that increases cell influx and proliferation at the site of
injury, finally leading to the development of the advanced
lesions that precede heart attack or stroke (Figure 1).
A major component of atherosclerotic plaques is the foam
cell: macrophages or smooth muscle cells containing large
amounts of lipid derived from low-density lipoprotein
(LDL). LDL is capable of diffusing passively through
endothelial cell junctions, and its accumulation is a pri-
mary event in atherosclerosis, though its uptake in native
form is not rapid enough to generate foam cells [30].
Native LDL, however, is oxidized in the sub-endothelial
region [31] or within the lysosome [16] by various proc-
esses likely mediated by free radicals or reactive oxygen
species (ROS). Extracellular oxidized LDL (oxLDL) under-
goes receptor-mediated uptake by macrophage type I or
type II class A scavenger receptors (MSR-A) [30], CD36
[32] and lectin-like oxLDL receptor-1 (LOX-1) [33,34].
Unlike the normal route of LDL uptake, these receptor-
mediated pathways are not regulated by cellular choles-
terol content and may lead to high intracellular levels of
oxLDL. Inhibition of MSR-A and CD36 has been shown to
reduce atherosclerotic plaque size [35] and foam-cell for-
mation [36]. Conversely, normal macrophages treated
with oxLDL quickly become foam cells, accumulating free
cholesterol (FC) and displaying reduced lysosomal
cholesteryl ester (CE) hydrolysis [37]. OxLDL is now
widely regarded as a primary factor contributing to the
development of atherosclerotic lesions, having been
found cytotoxic to a variety of cell types. OxLDL also pos-
sesses a number of other atherogenic properties, such as
inhibition of cholesterol efflux, increased expression of
cellular adhesion molecules, and stimulation of macro-
phage proliferation [38-41]. Taken together, these proper-
ties may lead to plaque instability, increasing the chance
of rupture.
After endocytosis, LDL is delivered to the lysosome, where
CE may be hydrolyzed and FC released. Lysosomal FC
egress is mediated by Neimann Pick C proteins Type 1 and
2 (NPC) [42], which are believed to transfer FC to accep-
tor vesicles or directly to the plasma membrane before
proceeding to the endoplasmic reticulum [43]. Typically
macrophages are protected from excess FC accumulationMicrobial Cell Factories 2009, 8:21 http://www.microbialcellfactories.com/content/8/1/21
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through acyl-coenzyme A:cholesterol acyltransferase
(ACAT) re-esterification in the cytosol and cholesterol
efflux. In atherosclerosis, however, intralysosomal FC
accumulation occurs, followed by CE accumulation [44].
This series of events has been observed not only in macro-
phages treated with oxLDL, but in aggregated LDL
(aggLDL) and CE dispersion particles (DISP) [45].
Acetylated-LDL (acLDL), however, is not able to achieve
FC accumulation, instead forming cytosolic CE inclusions
[46]. This is curious, because acLDL is endocytosed by
MSR-A, as is oxLDL. AcLDL is not endocytosed by LOX-1,
however [33], and was not found to induce apoptosis at
the concentration of oxLDL. Similarly, native LDL and
cholesterol could not initiate apoptosis at as low of a level
as oxLDL [47].
Recent research shows that intra-lysosomal FC accumula-
tion inactivates the vacuolar-ATPases that maintain lyso-
somal pH, likely by partitioning to the lysosomal
membrane and exerting a direct effect on the proteins
[37]. This drop in pH subsequently inactivates acid lipase
and other hydrolases, leading to CE accumulation. And
while it may seem obvious that the unregulated uptake of
modified LDL through scavenger receptors could provide
the excess FC, the question arises as to why acLDL does
not cause the same accumulations, especially considering
aggLDL and DISP are unoxidized as well. Answers to this
may lie in the resistance of oxLDL to lysosomal degrada-
tion [48] and to the observation that acLDL is degraded
even more rapidly than native LDL [49]. OxLDL is also
more resistant to degradation than either aggLDL or DISP
[45], and it is also possible that aggLDL and DISP are oxi-
dized within the lysosome [16].
Many of the effects of oxLDL, including cytotoxicity, can
be attributed to one of its primary components, 7-ketoc-
holesterol (7KC) (Figure 2) [39]. The average LDL particle
contains approximately 600 molecules of cholesterol and
1600 molecules of cholesteryl ester (CE), all of which are
susceptible to oxidation prior to and during uptake [50].
Coronary heart disease Figure 1
Coronary heart disease. A, Fibrous plaque from a 65-year 
old white male showing lipid-laden smooth muscle cells 
(SMCs) (short arrows). Cells vary greatly in size and some 
appear to be coalescing (long arrows). The SMC nucleus is 
flattened against the side of the lacunar space (open arrows). 
B, High-power view of the subendothelial area from A. Foam 
cells (white arrows) have formed beneath the endothelium 
and lumen (asterisk). Two large, lipid-filled spaces likely 
formed by the joining of adjacent SMCs that are now dead 
(black arrows). C, Micrograph of a coronary artery cross-
section narrowed by a plaque. Images A and B courtesy of 
ncbi.nlm.nih.gov. Image C courtesy of genome.gov.
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7-ketocholesterol Figure 2
7-ketocholesterol. 7KC is an oxidized derivative of choles-
terol with cytotoxic properties. It has been associated with 
atherosclerosis as well as Alzheimer's disease and is thought 
to destabilize cellular membranes due to its altered physico-
chemical properties. It is found in high concentrations within 
atherosclerotic plaques and can be produced from choles-
terol by Aβ.
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Non-enzymatic oxidation of cholesterol predominately
occurs at the 7-carbon of the steroid nucleus, a region
associated with the greatest cytotoxicity [18,39,40,51,52].
Similar to cholesterol, 7KC partitions intracellularly to the
plasma and organellar membranes [53], though its
slightly higher polarity alters their biophysical properties
[54,55]. Several studies have found 7KC to increase disor-
der in membrane structure, altering curvature and the
properties of nearby membrane-bound proteins [56,57].
Incubation of U937 cells with 7KC caused lysosomal and
mitochondrial membrane permeablization in a sequen-
tial manner, ultimately inducing either apoptosis or
necrosis [51]. Eukaryotic cells contain at least two separate
calcium-dependent apoptotic pathways: one modulated
by calpain and the other calpain-independent [58]. Cal-
pain has also been implicated in neuronal death follow-
ing ischaemic insult by initiating lysosomal rupture and
subsequent cathepsin B release [59,60]. The ability of 7KC
to disrupt cellular Ca2+ homeostasis is likely integral to its
toxicity [61-63]. Evidence for this is also supported by the
prevention of 7KC-induced mitochondrial damage
through the addition of calmodulin inhibitors [64]. How
7KC induces Ca2+  influx is still a matter of research,
though it was found that it and several other oxysterols
could increase ion conductivity in membranes lacking
proteins [65].
Due to its high concentration in atherosclerotic plaques
[66-68], cytotoxicity, and other pro-atherogenic proper-
ties, 7KC is a prominent target for medical bioremedia-
tion. Contributing to the rationale for its elimination is
that 7KC has also been associated with Alzheimer's dis-
ease by several studies [69-71]. While FC alone has the
ability to destabilize lysosomes and hinder CE hydrolysis,
the etiology of atherosclerosis is clearly a complex process,
and 7KC certainly contributes. Reducing levels of 7KC
may subsequently reduce the rate of LDL uptake and
apoptosis, slowing atherosclerotic progression.
So how would it be possible to mitigate the effects of 7KC
in vivo? A number of transformations may reduce its toxic-
ity, with the most obvious example being side-chain
hydroxylation. The addition of an oxygen-containing
group to the 24- or 27-carbon of the cholesterol side chain
increases its ability to traverse cell membranes and allows
migration through the blood-brain barrier for easier excre-
tion [72,73]. Sterol 27-hydroxylase catalyzes the forma-
tion of 27-hydroxycholesterol, the most abundant
oxysterol found in atherosclerotic plaques, and is present
in macrophages as well as the liver and several other
organs [74-76]. It was also found to utilize 7KC as a sub-
strate, facilitating its secretion [77]. Unfortunately, high
levels of 27OH-7KC still accumulate in lesions and foam
cells. This may indicate that expression of sterol 27-
hydroxylase alone is not sufficient to overcome athero-
sclerotic progression or that the enzyme is not expressed
highly enough to compensate for the increased choles-
terol and oxysterol burden.
Another potential route of remediation would be removal
of the 7-keto moiety, which generates cholesterol, reduc-
ing toxicity to corresponding levels. A mechanism was
recently discovered through which 7KC is reduced to 7β-
hydroxycholesterol (7β-OH-Ch) by 11β-hydroxysteroid
dehydrogenase type 1 [78]. 7β-OH-Ch, however, is more
cytotoxic than 7KC; thus, hydrolysis of the hydroxyl group
would be necessary. Conversion of 7KC to 7α-OH-Ch is
preferable, as the latter has a much reduced toxicity and is
normally formed as an intermediate in the production of
bile acid in the liver by cholesterol 7α-hydroxylase [79].
Because an enzyme catalyzing the removal of the 7-OH
group is not endogenous to humans, this function would
have to be supplied exogenously. Our lab recently found
evidence of a hydrolase in Rhodococcus jostii RHA1 capable
of removing a 7-OH group from 7-hydroxycholesterol
and a number of its metabolites. Research is being per-
formed to see if this enzyme will be an effective catalyst in
human foam cells.
In our studies of Rhodococcus jostii RHA1 and in an assay
of environmental samples we obtained from soil and acti-
vated sludge, we discovered a wide variety of bacteria able
to mineralize 7KC [80]. Since RHA1 was known to
degrade cholesterol and the pathway previously character-
ized [81,82], we evaluated its ability to degrade 7KC and
performed a transciptomic and metabolite analysis (sub-
mitted). As hypothesized, 7KC follows a degradative path
similar to cholesterol, though it may utilize multiple iso-
zymes to accommodate the 7-keto substituent prior to its
elimination. This pathway involves simultaneous side
chain removal and ring cleavage. Humans, however, lack
the ability to cleave the ring structure of sterols; so this
ability would have to be supplied exogenously. Steroid
ring fission may facilitate endogenous enzymatic attack in
humans, though this is a purely speculative idea and it is
unclear what effect the byproducts would have.
Another potential target for medical bioremediation is CE
and oxidized CE. It has been theorized that oxLDL could
accentuate accumulation of CE through inactivation of
lysosomal acid lipase (LAL). In fact, exogenous supple-
mentation with lysosomal acid lipase was previously
shown to reduce the size of atherosclerotic plaques in
mice [83].
Though much work remains to be done, the therapeutic
value of medical bioremediation in treating atherosclero-
sis should soon be tested. The broad diversity of organ-
isms displaying the ability to degrade oxysterols provides
a wide range of enzymatic mechanisms that can not onlyMicrobial Cell Factories 2009, 8:21 http://www.microbialcellfactories.com/content/8/1/21
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effect the transformation of 7KC, but also cholesterol or
other sterols that may contribute to the pathogenesis of
atherosclerosis.
Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenera-
tive disorder that increasingly affects millions worldwide
and is the greatest cause of dementia in Western society. It
is estimated that US annual incidence rates will surpass
950,000 by 2050, affecting 62% of those 85 and older
[84]. It has also been estimated that delaying the onset of
AD by just two years would decrease the number of cases
in the US in 50 years by approximately two million [85].
AD is characterized by two neuropathological hallmarks:
senile plaques composed primarily of extracellular amy-
loid beta (Aβ) deposits [86,87] and neurofibrillary tangles
(NFT) generated from intraneuronal accumulations of
abnormal tau protein. Aβ is a peptide of 39–43 amino
acids formed by successive cleavage of amyloid precursor
protein (APP) by β- and γ-secretases. While Aβ40 is the
most common isoform, Aβ42 is most typically associated
with progression of AD, accumulating first intracellularly,
where it alters the normal metabolism of APP and pro-
motes lysosomal APP accumulation [88] (Figure 3). Tau
proteins are microtubule-associated proteins with six iso-
forms that exist in brain tissue. Hyperphosphorylation of
tau causes self-assembly into paired helical filaments that
are present in AD and several other tautopathies [89].
The amyloid-cascade hypothesis purports that errors in
metabolism of APP are the initiating events in AD patho-
genesis, subsequently leading to the aggregation of Aβ
(more specifically Aβ42) and eventually plaque formation
[19,90,91]. Aβ is thought to catalyze the formation of
NFTs [84,92,93], affecting tau proteins through regulation
of glycogen synthase kinase-3 (GSK3) activity [94,95] and
activation of cyclin-dependent kinase 5 (CDK5) [96].
CDK5 is inactive in its monomeric form and needs p35
for activation, but when cells undergo oxidative injury or
treatment with Aβ42, p35 is cleaved by calpain to form
p25. This increases the stability of the p25-CDK5 com-
plex, alters its subcellular localization, and eventually
results in the hyperphosphorylation of tau [97]. Another
relationship between Aβ and tau is their effect on axonal
transport, deficiencies of which may promote pathologi-
cal development. APP is a potential receptor for the
kinesin light chain [98], a microtubule motor, and tau has
been found to inhibit kinesin-dependent transport [99].
Transport deficiencies have been found to selectively
increase Aβ levels and amyloid depositions in the affected
regions [100].
The number of relationships among Aβ, tau, and other
proteins or disease processes is staggering and beyond the
scope of this review; however, it should be noted that
many factors involved in AD have also been found deter-
minate of other pathologies. For example, over 100 genes
have been found to be associated with AD, and many of
these are also highly correlated with atherosclerosis
[70,71]. In fact, APP and Aβ can oxidize cholesterol to 7β-
hydroxycholesterol, which can be subsequently oxidized
to 7KC [101]. Another association between atherosclero-
sis and AD are the parallels found between NPC and both
diseases [102]. Lysosomal dysfunction likely has a pri-
mary role in all of these processes [103]. Relationships
between frontotemporal dementias, Parkinson's disease,
and AD have also been discovered [104]. These may be a
result of inflammatory processes, increased tissue trans-
glutaminase [105], or some other factor, but usually the
causes of pathogenesis are attributed to just a few com-
pounds. In AD, this is Aβ or tau proteins, both of which
may be useful targets for medical bioremediation.
Evidence for the efficacy of eliminating Aβ from senile
plaques in the treatment of AD was first reported in mice
genetically modified to develop Aβ plaques and subse-
quently immunized with Aβ42 [106]. This resulted in
reduced Aβ plaque formation, astrogliosis, neuritic dys-
trophy, and improved cognitive function. Aβ42 immuni-
zation was able to significantly slow the decline in
cognitive function in patients with AD. Unfortunately,
post-vaccination meningoencephalitis was seen in a
Amyloid accumulation in Alzheimer's disease Figure 3
Amyloid accumulation in Alzheimer's disease. PET 
scans reveal Aβ deposits in the brains of three patients with 
AD (left) and three normal patients (right). Yellow areas indi-
cate high levels of uptake of an Aβ label while red signifies 
medium uptake. Image courtesy of lbl.gov.
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number of patients [107], and follow-up studies deter-
mined that Aβ42 clearance did not prevent progressive
neurodegeneration [108]. This may be attributed to over-
activation of the innate immune system, where a pro-
inflammatory response could compromise the potential
improvements of plaque reduction. For this reason,
plaque reduction using a more transient approach might
be valuable in determining the usefulness of Aβ clearance
for treatment of AD. It has also been observed that the
patients had tau pathology disseminated across the entire
cortex [109], implying that elimination of both Aβ and
tau may be necessary to achieve a reversal or slowing of
disease progression. Animal studies, however, indicate
that Aβ immunotherapy is capable of also clearing early
stage hyperphosphorylated tau, but not late aggregates
[110].
Immunotherapy targeting for hyperphosphorylated tau
[111] and α-synuclein [112] has been proven effective for
clearing each compound in mouse models of tau pathol-
ogy and Parkinson's disease respectively. Similar to stud-
ies on Aβ immunization [110], the study on tau
immunotherapy also revealed that treatment at an early
stage was substantially more effective at preserving motor
coordination than action taken at later stages of func-
tional impairment. This implies that preventative meas-
ures taken before symptoms of AD appear may be most
effective. This may well be true for all insoluble aggregates
of physiologically soluble proteins.
Aβ and tau clearance may be better achieved using tran-
sient expression of enzymes capable of catalyzing their
degradation. Additionally, the targeting of intracellular Aβ
may overcome some of the limitations of antibody-medi-
ated therapies used to clear extracellular accumulations.
Microglia in the CNS were found to impair Aβ-degrading
capability, leading to its lysosomal accumulation. Aug-
mentation with mannose-6-phosphorylated hydrolytic
enzymes, however, increased Aβ degradation [113].
Although these researchers did not identify the enzymes
involved, numerous enzymes already are known to be
capable of degrading Aβ. These include neprilysin (NEP)
and its homologue endothelin-converting enzyme (ECE1
and ECE2), insulysin (IDE), angiotensin-converting
enzyme (ACE), and matrix metalloproteinase-9 (MMP-9).
Each of these enzymes has a different subcellular localiza-
tion, and their use as therapeutics for treatment of AD has
already been proposed [114,115]. NEP gene transfer has
previously been found to reduce amyloid deposits in
transgenic mice [116,117]. Recently, Carty et al. used
recombinant adeno-associated virus (rAAV) to over-
express ECE in the right anterior cortex and hippocampus
of mice, resulting in Aβ reduction [118]. However, expres-
sion of these endogenous proteases poses certain risks due
to their promiscuous specificity. For example, NEP is
known to degrade many substrates with important physi-
ological functions such as enkephalins, substance P, and
endorphins [115]. It may be necessary to increase sub-
strate specificity through protein engineering of these par-
ticular enzymes to avoid deleterious consequences.
Alternatively, proteases with increased substrate specifi-
city may be identified by assaying microbial cultures for
the ability to degrade amyloid. In fact, Aβ degradation was
recently seen in cell cultures contaminated by Mycoplasma
hyorhinis. Several other species of mycoplasma are known
to be pathogenic and express proteins capable of degrad-
ing components of the extracellular matrix. Partial
sequencing of the M. hominis genome predicted at least
three metallopeptidases, and M. penetrans is expected to
express oligopeptidase O1, a metallopeptidase from the
neprilysin family [119]. Some of these enzymes may
prove useful tools for remediating Aβ aggregates, either
through enzyme replacement or gene therapy.
Advanced Glycation End-Products
Advanced glycation end-products (AGEs) result from
pathways initiated by Maillard reactions between free
amines and aldehydic sugars such as glucose. This can
result in irreversible glycation and cross-linking of endog-
enous proteins inside and outside of cells [120]. The first
semi-long-lived intermediate of the Maillard reaction is
the amadori product called fructosyl lysine. Because of its
carbonyl moiety, fructosyl lysine is prone to further attack
by primary amines and rearrangement. This gives rise to
the heterogeneous mixture of sugar-derived protein
adducts summarized as AGEs. Some AGEs are plain
adducts to the affected lysine residues, while others may
crosslink two or more amino acids from different pro-
teins.
Among the large variety of AGE structures known, only a
few seem quantitatively important enough to have major
effects in vivo [121] (Figure 4). Glucosepane is by far the
most abundant known AGE crosslink [122], and its cleav-
age is thought to be the most important current objective
in AGE remediation [123]. Carboxymethyl lysine (CML)
is also of considerable importance, as it has been impli-
cated not only in extracellular matrix dysfunction [124],
but has also been suggested to compromise intracellular
protein turnover, due to increased glycation of the 26S-
proteasome with aging [125]. CML is a non-crosslinked
AGE and would, therefore, potentially be the easier target
for removal, because access of an enzyme to the AGE may
be sterically less impaired, while the chemistry of its cleav-
age would seem much simpler than in other AGEs.
Proteolytic turnover seems to be a major pathway of AGE
removal in human tissues. The resultant free amino-acid
AGEs are readily excreted by healthy kidneys and other
pathways [126] and are of quantitatively minor impor-Microbial Cell Factories 2009, 8:21 http://www.microbialcellfactories.com/content/8/1/21
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tance in comparison to diet-derived free amino-acid
AGEs. Thus, AGE modification of most short-lived pro-
teins is thought to be relatively unproblematic. However,
some extracellular matrix proteins are so long-lived that
significant turnover does not occur within the human life-
span. In these proteins (such as certain tissue collagens
and lens crystallins), AGEs accumulate with throughout
the life span [127]. Because AGEs derive from glucose,
they are more abundant and accumulate faster in diabetic
patients [128]. AGEs in (long-lived) collagens appear to
be better predictors of diabetic complications than those
in (short-lived) hemoglobin [129]. Extracellular matrix
dysfunction as a consequence of AGE-accumulation is
thought to contribute to an array of conditions related to
aging and diabetes, including atherosclerosis, amyloido-
sis, cataracts, retinopathy, neuropathy, nephropathy, and
impaired wound healing [130].
AGEs in long-lived proteins are thought to contribute to
pathology via two mechanisms. First, by altering the func-
tional groups of amino acids, AGEs may be detrimental to
the affected protein's function. In particular, cross-linking
of extracellular matrix proteins by AGEs may reduce the
mechanical compliance of the tissues, making them more
brittle and less able to sustain mechanical stress with age
[131]. Second, AGEs are recognized by receptors of AGEs
(RAGEs), which modulate inflammatory signaling. With-
out neutralization of the causative agent, chronic inflam-
mation is thought to promote many age-related diseases
[132]. Attempts to attenuate the pathology mediated by
AGEs include pharmacological inhibition of the AGE-
RAGE interaction, inhibition of their formation, and
pharmacological breakage of existing AGEs. Phenylacylth-
iazolium compounds have been shown to catalytically
cleave the α-diketone crosslink, a hypothetical AGE, in
vitro [133], and they may have clinical benefits relating to
vascular compliance in aged and diabetic patients [134].
However, the α-diketone crosslink has not been demon-
strated to occur in vivo, and the mechanism of action of
this class of compounds remains unclear. No breakers of
uncontroversial AGEs in vivo are currently known. It
appears that the potential of small molecules to specifi-
cally catalyze such difficult reactions may be limited.
Because only AGEs in long-lived proteins are thought to
play a role in major age-related conditions, a key require-
ment for any AGE-breaking therapeutic may be the ability
to repair AGE-modified proteins, as opposed to merely
AGE-modified free amino acids. So far, several examples
of AGE-breaking enzymes have been reported that illus-
trate this requirement. Vincent Monnier et al. [135] began
targeting fructosyl lysine, the common precursor to most
AGEs, as early as 1994. Using enrichment cultures, they
isolated microorganisms that could subsist on fructosyl
lysine. They also isolated strains capable of utilizing steri-
cally impaired analogs, such as fructosyl adamantyl
amine, as the sole carbon and energy source. This led to
the identification of several amine-oxidase type enzymes,
called amadoriases, capable of deglycating free fructosyl
lysine [135]. However, this class of enzyme does not work
on substrates larger than a few amino acids [136]. Further-
more, the amadoriase have resisted extensive attempts of
protein engineering to make them work on larger sub-
strates. Recently, detailed structural information has been
published, which may explain why this is problem has
been so intractable [137].
Van Schaftingen et al. isolated another group of deglycat-
ing enzymes from a variety of bacteria as well as humans,
the fructosamine kinases. E. coli fructosamine-6-kinase
(F6K) phosphorylates fructosyl lysine [138], thereby flag-
ging it for cleavage by a subsequent deglycase [139]. How-
ever, neither the kinase nor the deglycase have been
shown to work on fructosyl lysine modified proteins.
Phosphorylation of fructosyl lysine by Fructosamine-3-
Advanced glycation end-products Figure 4
Advanced glycation end-products. Two of the most 
abundant AGEs are glucosepane and carboxymethyl lysine. 
AGE modification of long-lived proteins contributes to extra-
cellular matrix dysfunction, leading to an array of conditions 
related to aging and diabetes. These include atherosclerosis, 
amyloidosis, cataracts, retinopathy, neuropathy, nephropa-
thy, and impaired wound healing.
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kinase (F3K) destabilizes the molecule, causing its sponta-
neous decomposition into lysine, without the need for a
deglycase [140]. F3K does work on proteins [141], and
this activity appears to constitute a mammalian erythro-
cyte glycation repair pathway [142]. However, the kinases'
ATP requirement is thought to make them unsuitable for
extracellular application.
Almost a decade ago, a CML-cleaving enzyme of the
amine oxidase family was discovered [143]. However, like
its relatives the amadoriases, it is reported that this
enzyme does not act on CML-modified protein. It is not
yet clear how amenable this enzyme may be to protein
engineering to make it work on larger substrates, or
whether other CML cleaving enzymes may exist.
No other AGE-cleaving enzymes have been reported. Due
to its abundance in collagen, it seems that glucosepane
cleavage would be the most important goal for therapeu-
tic application [144]. However, the chemistry involved in
cleaving this lysine-arginine crosslink seems highly intrac-
table. At least four bonds must be cleaved to yield the
native amino acids, lysine and arginine. Also, access of a
cleaving enzyme to the substrate must be even more
strongly impaired in the case of glucosepane, because it is
a protein-protein crosslink. No attempts to accomplish
this have been published.
Age-related Macular Degeneration
Age-related macular degeneration is the most frequent
cause of blindness in the elderly [145]. The disease is char-
acterized by progressive apoptosis of retinal pigment epi-
thelial (RPE) cells, inflammation, extracellular matrix
changes, and sometimes aberrant vascularization of the
tissue [146]. A large array of pathological mechanisms
identified in animal models and human SNP analyses has
recently been reviewed [147]. One prominent feature of
the disease is the accumulation of pathogenic materials,
such as extracellular drusen and intracellular lysosomal
lipofuscin (Figure 5).
Drusen are extracellular deposits between the retinal pig-
ment epithelium and Bruch's membrane. Small "hard"
drusen are normal features of aging and considered non-
pathogenic. In macular degeneration, drusen become
larger and diffuse (i.e., "soft"). They contain an array of
molecules thought to be actively involved in macular
degeneration, such as inflammatory signaling molecules,
microglial cells, cell debris, components of the comple-
ment system, VEGF, cholesterol, and lipids [148]. These
molecules can be modified by protein misfolding, oxida-
tion, and glycation. The heterogeneous nature of the
drusen might make it difficult to target these aggregates
with catabolic enzymes directly. However, if key modifica-
tions could be targeted (such as oxidated or glycated resi-
dues), this might render the drusen more amenable to
clearance by endogenous mechanisms.
Lipofuscin is a heterogeneous mixture of indigestible mol-
ecules that accumulate in post-mitotic cells [149]. RPE
lipofuscin is different from other lipofuscin in that it con-
sists mostly of vitamin-A derived fluorescent compounds,
such as the pyridinium bisretinoid A2E (Figure 6). The
role of the retinal pigment epithelium is to nourish and
support the photoreceptors. A key aspect of this role is the
visual cycle, which serves to recycle retinylaldehyde spent
in the process of vision. An intermediate of the visual
cycle, all-trans retinal, is thought to be the precursor of
A2E [150]. And while A2E arises as a by-product of the vis-
ual cycle, when retinal reacts with membrane-bound eth-
anolamine in a rare side-reaction, over the entire life span
the total amount of A2E accumulation can be substantial:
in aged RPE cells A2E can fill up to 20% of the cell's vol-
ume.
A2E has multiple known pathogenic effects. With its
hydrophobic side-chains and charged centers, A2E is
thought to act as a detergent on membranes. Thus, load-
ing cultured RPE cells with A2E can cause rupture of the
plasma membrane, resulting in leakage of cytosolic con-
tents from the cells [151]. Furthermore, the compound
can bind to and inhibit lysosomal ATPase, the enzyme
responsible for maintaining an acidic pH [152]. The lyso-
somal pH in cultured RPE cells containing A2E is compro-
mised, possibly to either or both of the above
mechanisms [153]. This would likely impair the activity
of other lysosomal enzymes, causing broad lysosomal
failure. Indeed, the ability of A2E-loaded RPE cells to
digest rod outer segments is impaired [154]. Third, A2E is
readily transformed into highly reactive species in vivo, by
both light and dark mechanisms. Dark mechanisms
(autooxidation) yield carbonyls [155]. Light mechanisms
Age-related macular degeneration Figure 5
Age-related macular degeneration. A, A2E deposits in 
the retinal pigment epithelial (RPE) cells and Bruch's mem-
brane of a senescent CCL2-/- mouse. B, Several round, yel-
low subretinal lesions in the same mouse. Images courtesy of 
nei.nih.gov.
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(phototoxicity) yield oxiranes [156]. Both types of com-
pounds may react indiscriminately with cellular nucle-
ophiles, including DNA. It is not yet clear which of the
above mechanism prevails in causing toxicity, if any.
Regardless of the mechanism(s) of toxicity, it seems quite
clear that selective enzymatic remediation of A2E would
offer a promising new treatment strategy.
The macula is the area of highest photoreceptor density in
the retina and serves high-acuity vision. It contains the
highest amount of retinol, the highest visual cycle activity,
and accumulates A2E the fastest. It is an interesting ques-
tion whether this may explain why the macula is the first
to be affected by age-related degeneration. A2E formation
begins by condensation of all-trans retinal with mem-
brane-bound phosphatidyl ethanolamine (PE). It is pos-
tulated that the resultant retinlyidene-PE is removed to
the outer leaflet by the flippase ABCR (ABCA4, RmP)
[157]. According to this model, only retinlyidene-PE that
escapes ABCR's flippase activity is available to condense
with a second molecule of all-trans retinal to form A2E.
This mechanism could be limiting the formation of A2E,
and counteracting macular degeneration. ABCR knockout
mice, as well as human patients suffering ABCR muta-
tions, accumulate A2E at an accelerated rate and develop
early onset macular degeneration (Stargardt's disease)
[157,158]. A2E degrading enzymes would help shed light
on the role of A2E in heritable and age-related macular
degeneration, and might have the potential to become
therapeutic agents.
Gene and Enzyme Discovery
In the previous sections, we provided a number of exam-
ples in which the abnormal accumulation of biological
"waste" leads to pathological conditions; this situation is
further exacerbated by the inefficiencies of cell function
found with increasing age. Observations that these accu-
mulations are often slow and progress over the course of
a lifetime indicate that the targeted degradation of these
deleterious compounds could have enormous therapeutic
value if performed before advanced pathology surfaces. In
several cases, recombinant human enzymes or antibodies
are being tested for their ability to clear these aggregates,
but this may upset cellular homeostasis if these enzymes
also target unintended substrates or their products are
components of regulatory networks. An alternative is the
use of xenoenzymes, or enzymes not native to the human
cells.
The high levels of diversity found within and among
microbial communities provides ample opportunity for
the bioprospecting of xenoenzymes capable of transform-
ing any energy-rich carbon-based compound. It has been
estimated that 4–6 × 1030 prokaryotic cells exist on earth
[159], representing between 106  to 108 different taxo-
nomic groups [160]. This is an enormous pool of largely
unexploited biological resources. Sifting through this
pool for useful enzymes, however, poses certain chal-
lenges. Often, the extent of diversity within a given sample
can exceed the capacity to effectively screen it. Histori-
cally, sample enrichment has been used to overcome this
limitation.
Whole-cell, genome, and gene enrichment are all means
of enhancing screening hit rates, improving the discovery
of target genes and their corresponding enzymes [161]
(Figure 7). Enrichment cultures, involving the use of selec-
tive medium for the isolation of one or a small group of
organisms, have been used for over a century for the study
of biocatalysis, and they help narrow library sizes for
effective screening. Our group has used them in conjunc-
tion with plating to isolate pure strains of bacteria capable
of degrading 7KC [80], and the technique has also been
used to identify lipofuscin degraders [162]. Logically, this
should be a useful technique for any of the targets we are
interested in for medical bioremediation due to the obser-
vation that none of these compounds accumulates in the
environment. The use of enrichment cultures does have
The pyridinium bisretinoid A2E Figure 6
The pyridinium bisretinoid A2E. A2E is derived from 
vitamin A aldehyde (retinal) and phosphatidyl ethanolamine. 
It accumulates in postmitotic retinal pigment epithelial cells 
over the life span, and it has been implicated in the ethiology 
of various forms of macular degeneration.
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some limitations, however: primarily that current cultur-
ing techniques yield a small fraction of the true microbial
diversity [160]. Recently, the development of metagen-
omic techniques [163] has provided a means to harvest
the entire genetic complement of environmental samples
independent of our ability to culture the microorganisms.
These techniques can be used in conjunction with mild
enrichment methods to increase screening hit rates,
though some loss of diversity will result.
Construction of a metagenomic library relies on effective
nucleic acid extraction techniques and cloning directly
from environmental samples. Although complete extrac-
tion is desired for an even representation of all microbial
genomes, this must occur with minimized DNA shearing
and as little co-extraction of contaminants as possible. In
addition, techniques must be optimized for isolating from
different environments [164,165]. Total DNA extraction
may also lead to an over-representation of a limited
number of dominant microbes. This may be partially
resolved using experimental normalization techniques
based on cesium-chloride gradient centrifugation in the
presence of an intercalating agent, which separates
genomes based on their GC content, or methods that
require the denaturation and reannealing of genomic
DNA. The principle behind the latter method is that abun-
dant ssDNA will re-anneal more quickly, and its extrac-
tion will result in an amplification of rare sequences
[166].
Genome enrichment often permits the detection and iso-
lation of DNA from metabolically active microbial popu-
lations that are not discernable using other techniques.
The two most widely used methods of analysis are stable-
isotope probing (SIP) and 5-bromo-2-deoxyuridine
(BrdU) labeling [167,168]. Genome enrichment by SIP
depends on the metabolism of 13C-, 18O-, or 15N-labeled
substrates and their utilization for DNA synthesis. The
heavier DNA or RNA from organisms catabolizing the
substrate can be separated by density gradient centrifuga-
tion. Wide application of this technique, however, is lim-
ited by the commercial availability of labeled
compounds. An alternative is BrdU labeling, which allows
the separation of DNA or RNA from community members
that are metabolically active, though not necessarily
degrading the desired substrate. Label recycling poses
problems for both of these methods.
Specific gene enrichment can be achieved by a number of
techniques, mostly related to either subtractive hybridiza-
tion or differential expression. Suppressive subtraction
hybridization (SSH) can be used to identify the genetic
differences between two bacteria or two complex popula-
tions, but does not provide information specific to the
genes of interest [169,170]. A more useful technique
Gene discovery flowchart Figure 7
Gene discovery flowchart. The search for novel biocata-
lysts begins with the enrichment of environmental samples. 
This may be culture, genome, or gene enrichment, and 
serves to narrow the library size for effective screening. 
After nucleic acid extraction (DNA or RNA), several ave-
nues are available for gene and enzyme discovery. These can 
include construction of a metagenomic library followed by 
functional screening, microarray analysis, or sequence-based 
assays. Final expression requires full-length gene expression 
in a heterologous host.Microbial Cell Factories 2009, 8:21 http://www.microbialcellfactories.com/content/8/1/21
Page 11 of 18
(page number not for citation purposes)
might be cDNA representational difference analysis
(RDA), which relies on mRNA isolation to identify dis-
similarities in gene expression. Briefly, cDNA libraries are
created using population samples grown under the condi-
tion of interest (e.g., in the presence of some substrate)
and without the particular condition. These are known as
the tester and driver samples, respectively. The derived
cDNAs are subjected to digestion and ligated to a syn-
thetic oligonucleotide. PCR is then performed using prim-
ers specific to the synthetic oligonucleotides, and the
products are digested with the same restriction enzyme.
For subsequent steps, the tester is ligated to a different
synthetic oligonucleotide and mixed with the driver.
Denaturing, annealing, and multiple rounds of PCR with
primers specific to the new oligonucleotide amplify
sequences unique to the tester in an exponential manner,
while other sequences are amplified linearly or not at all
[171,172].
The creation and screening of a metagenomic library
involves molecular biology methods that have been
developed and utilized for over thirty years. One impor-
tant limitation, however, is achieving gene expression in a
surrogate host, which is needed for activity-based screen-
ing. The probability of a specific gene being expressed is
determined by not only its abundance in the environ-
ment, but the insert size, gene length, and expression ele-
ments. At a minimum, expression elements must include
the cis-acting sequences for a promoter and ribosomal
binding site (RBS) that are functional in the host. Addi-
tional trans-acting elements that may need to be present in
the host include transcription factors, chaperones, cofac-
tors, or secretory machinery, to name just a few. The cis-
acting sequences may be engineered into the cloning vec-
tor; however, the necessity of trans-acting elements is dif-
ficult to determine. In looking at options for the
incorporation of cis-acting sequences, three possible alter-
natives surface: 1) provision of promoter and RBS from
insert, also known as independent gene expression, 2)
expression as a fusion using only the RBS from the insert,
and 3) expression as a fusion using both promoter and
RBS from the vector. Unfortunately, the latter two meth-
ods achieve such low frequency of functional constructs
that the required number of clones would be too large for
most screening assays. Independent gene expression in E.
coli, while only achieving approximately 40% recovery of
enzymatic activity, allows for the creation of much smaller
libraries [173]. The use of alternative hosts should allow
for greater recovery.
Combining enrichment methods with differential expres-
sion technology, such as microarrays, is a powerful
method for quickly identifying a large fraction of genes
involved in degradation of a particular substrate. In our
lab, we were able to identify a Rhodococcus sp. capable of
degrading 7KC through enrichment cultures. Microarray
slides were available for a closely related species, Rhodococ-
cus jostii RHA1, and we utilized them for the identification
of a number of genes involved in catabolism of 7KC (sub-
mitted). Unfortunately, the availability of sequence infor-
mation is often a prerequisite for microarray slide
construction, and when studying a small subset of genes,
the prospect of genome sequencing may exceed the time
and funding available for a project. One possible solution
is the use of a shotgun DNA microarray strategy, which
sidesteps the need for sequence information [174,175].
Once an enzyme(s) capable of degrading the target com-
pound has been identified, it must be screened for specif-
icity and the ability to remain active under physiological
conditions. Specificity is critical to limit the amount of
undesirable catabolism that may potentially disrupt cellu-
lar homeostasis. For example, we would like to target 7KC
degradation, but cholesterol degradation might not be
desirable due to its function in maintaining membrane
fluidity. However, considering the number of possible
substrates that would have to be screened for each target
and the potential lack of commercial availability, in vivo
assays should be used in conjunction with in vitro assays.
An exhaustive list of assays would be beyond the scope of
this review; however, for protein substrates, which would
have the largest diversity space, substrate profiling offers a
high-throughput method for screening proteases [176].
Additionally, substrate specificity as well as other opera-
tional properties can be modified through protein engi-
neering [177-179].
Enzyme Drug Delivery
The best way to deliver therapeutic enzymes to human cell
lysosomes may be to mimic currently marketed "Enzyme
Replacement Therapy" (ERT) drug-delivery routes for her-
itable lysosomal storage diseases [180-182]. These strate-
gies are based on an affinity interaction of certain "tags"
on the enzyme, with a specific endocytic cell surface recep-
tor; binding of the enzyme to the receptor results in endo-
cytosis. According to the classic endocytic route, the
endosomes then fuse with lysosomes, resulting in targeted
delivery. Thus, enzyme drug delivery to lysosomes is, in
our view, mostly a question of which affinity tag/cell sur-
face receptor pairs to use.
In current ERT, two main receptors are used for delivery:
the mannose receptor, which is found mostly on macro-
phages, and the cation-dependent mannose-6-phosphate
(M6P)/Insulin-Like Growth Factor 2 receptor (IGF2R),
which is found on most cell types [183]. Macrophages are
the affected cell types in Gaucher disease, and recom-
binant glucocerebrosidase is delivered by this route [184].
Other lysosomal-storage diseases, such as Fabry, are dis-Microbial Cell Factories 2009, 8:21 http://www.microbialcellfactories.com/content/8/1/21
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eases that affect most cell types, and the therapeutic is
delivered by the M6P/IGF2R route [185].
Using the mannose receptor depends on our ability to
manufacture a recombinant therapeutic protein present-
ing mannose residues at the termini of its glycosylation
trees ("mannose-terminated" enzyme). For this purpose,
the N-glycosylation apparatus of the endoplasmic reticu-
lum (ER) in eukaryotic cells is usually used. Nascent pro-
teins are synthesized into the ER, while protein folding
and glycosylation happen co-translationally. This requires
the consensus glycosylation sites "NX(S/T)" to be present
on the recombinant protein. If the source of the protein is
foreign, or it is not natively glycosylated, then such sites
will need to be created on the surface of the protein. Fur-
thermore, NX(S/T) is so short that it may randomly occur
or be introduced through point mutations. Thus, internal
glycosylation sites will likely need to be removed to per-
mit proper protein folding during the co-translational
folding/glycosylation process.
In higher mammalian cells, proteins that receive the core
mannose residues in the ER will then be transported to the
Golgi apparatus for attachment of higher glycosylations,
such as sialic acid [186]. From an ERT point of view, this
is undesirable, because the higher sugars will obscure the
mannoses and prevent mannose receptor binding.
A few solutions to this problem have been explored. The
protein may be treated with glycosidases to remove the
higher glycosylations [187]. The protein may be produced
in a host that does not use higher glycosylation, such as
insect cells [188]. A less well tested possibility may be to
use an ER-retention signal (KDEL) to prevent exposure of
the recombinant enzyme to golgi-bound higher glycosyl
transferase activity.
As the name implies, the mannose-6-phosphate/IGF2
receptor (M6P/IGR2R) is a bifunctional protein – it has
distinct binding sites for mannose-6-phosphate and IGF2.
It acts as a scavenger for constructs bearing either tag. It is
not a signaling receptor, but only responsible for the lyso-
somal delivery of its substrates for destruction. M6P/
IGF2R is also found in the Golgi apparatus, where it
directs newly synthesized lysosomal proteins bearing
M6P to the lysosome. Due to its natural relevance to lyso-
somal delivery, traditionally only M6P was used for ERT
via M6P/IGF2R. However, M6P attachment sites on lyso-
somal enzymes are complex and poorly understood.
Thus, it is not trivial to attach M6P tags to enzymes that
are not natively lysosomal. One way of doing the attach-
ment may be to create a translational fusion of the recom-
binant therapeutic and a native lysosomal enzyme, in
order to "piggy-back" into the lysosome.
A second drawback of using M6P is that the macrophage
mannose receptor may internalize M6P-modified protein,
clearing it from the bloodstream before it reaches its other
cellular destinations[183]. This could be either be due to
M6P directly binding to the mannose receptor or to
incomplete phosphorylation, leaving some mannose res-
idues intact, which may then bind to mannose receptor.
In either case, having an affinity reagent, other than M6P,
that would be selective for the M6P/IGF2 receptor may cir-
cumvent this problem and enhance delivery to non-mac-
rophage cell types.
One group recently realized that IGF2 as a peptide-tag on
their enzyme could achieve lysosomal delivery as well as
an M6P tag. This idea was named the glycosylation-inde-
pendent targeting (GILT) system [189]. Furthermore,
IGF2 as a peptide has several advantages over sugars. It
can be produced easily and cheaply in a bacterial host.
GILT-bearing constructs are not as efficiently cleared from
the bloodstream as M6P-bearing constructs, presumably
because they do not bind macrophage mannose receptor.
This allowed a smaller dose of enzyme to reach its
intended target cell lysosomes more efficiently in an ani-
mal model [189]. Thus, GILT might a priori seem to con-
stitute an acceptable route to deliver xenoenzymes for
medical bioremediation to M6P/IGF2R presenting cells.
In summary, it appears that, for the major targets of med-
ical bioremediation – oxysterols, A2E, and AGEs, delivery
routes targeting xenoenzymes to their respective destina-
tions are conceivable. The macrophages (oxysterols,
atherosclerosis) can be addressed by the mannose recep-
tor. The retinal pigment epithelium (A2E, macular degen-
eration) has mannose and M6P/IGF2 receptors, and it
may be addressable by either or both routes [190]. Those
AGEs thought to be most pathologically relevant are extra-
cellular, and they may be accessible without any special
enzyme-uptake system.
While ERT may arguably be the most promising form of
enzyme delivery for many applications, most lysosomal
storage diseases affect the central nervous system (CNS),
which is protected by the blood-brain barrier (BBB) [191].
The BBB prevents transport of most chemicals and larger
particles from the blood into the brain, while selectively
allowing uptake of substances necessary for normal meta-
bolic function. Most enzymes used in ERT cannot cross
the BBB; hence, an alternative means of treating the CNS
is necessary.
One option is to use the transferrin receptor (TfR) to facil-
itate transport of therapeutic enzymes across the BBB. This
has been achieved in adult mice using monoclonal anti-
bodies (mAb) specific to the TfR conjugated to bacterial β-Microbial Cell Factories 2009, 8:21 http://www.microbialcellfactories.com/content/8/1/21
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galactosidase, a 116 kDa protein [192]. Additionally, the
TfR was used to deliver plasmid DNA encoding a lyso-
somal enzyme, β-glucuronidase to the brain. The plas-
mids were encapsulated in liposomes containing the
TfRmAb and intravenous administration was able to bring
CNS levels of β-glucuronidase to therapeutic range [193].
Furthermore, these methods were able to delay enzyme
clearance in respect to unmodified enzyme due to
removal from the blood by the liver and spleen. Ex vivo
gene therapy has also been used to genetically modify
autologous fibroblasts to produce neuronal growth factor
(NGF) in the forebrain after grafting [194]. This method
could theoretically be used for production of any enzyme
in the brain.
Another potential roadblock to the success of ERT is the
induction of antibodies to the replacement enzymes by
the adaptive arm of the immune system. This is thought
to be particularly severe in patients with no detectable lev-
els of the enzyme levels of interest [195] and can greatly
reduce the efficacy of treatment. To these patients, the
recombinant replacement enzyme appears immunologi-
cally foreign. Fortunately, at least three means are availa-
ble to prevent or attenuate an antigenic response. An
immunosuppressive regimen may be useful to reduce or
eliminate antibody responses against the recombinant
enzyme in many cases [196]. Treatment recipients also
may be conditioned for antigen tolerance through regula-
tory T-cell activation [197,198]. Additionally, proteins
may be generated to be immunologically invisible
through the incorporation of a specific sequence from
Epstein-Barr virus nuclear antigen I that prevents proteo-
somal degradation of linked antigens [199].
It can be expected that recombinant enzymes from foreign
species will face a similar problem. However, when target-
ing the age-related aggregates discussed above, the situa-
tion may be different in several respects. The first major
difference is that age-related aggregates accumulate much
more slowly than the aggregates in congenital lysosomal
storage disorders. For example, AGEs are thought to accu-
mulate only in long-lived proteins, in a process that lasts
for the entire life-span [200]. Similarly, lipofuscin accu-
mulations and atherosclerotic lesions grow slowly and in
a linear way over the life span. Thus, treatment with the
recombinant enzyme may be much less frequent than it is
for congenital lysosomal storage disorders. In the ideal
case, a highly active enzyme might be administered once
in old-age to degrade most of the aggregate present in the
body at that time, but before an adaptive immune
response has time to develop. The aggregate would then
need another life-time to accumulate once again. But even
if this ideal case is not achievable, then a transient aggres-
sive immunosuppressive regimen may be used in a con-
trolled hospital environment, where the patient is at little
risk for infection for as long as the therapy is required.
Due to the age-related nature of the aggregates, it seems
unlikely that continuous treatments will be required,
where an adaptive immune response would be a major
complication.
Conclusion
The harnessing of microbial catabolic capacity for the
treatment of age-related disease offers new therapeutic
options for some of the most common maladies of West-
ern society. Since the idea of medical bioremediation was
first conceived several years ago [4,5], technical barriers
have been overcome, and knowledge has developed that
further substantiates its potential feasibility. For example,
bacterial enzymes have been expressed in the lysosomes
of mammalian cells [201], techniques exist to circumvent
the problem of crossing the blood-brain barrier
[118,193], and methods of inducing immune tolerance
are being actively developed [202-204]. However, wide-
spread implementation of medical bioremediation will
depend on the success of trials that will test its efficacy and
safety. Our own labs are actively identifying enzymes
capable of degrading several important targets; new col-
laborations and an expanded awareness of this therapeu-
tic option would provide the academic and commercial
support necessary to accelerate the development of treat-
ments.
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